医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1593 医美概念股

端午节休市 06-18 16:00:00

842.621

+2.201

+0.26%

最高862.084	最低827.598	成交量7,436万
今开840.493	昨收840.420	日振幅4.10%
总市值0.00	流通市值0.00	总股本0.00
成交额8.16亿	换手率--	流通股本0.00
市净率1.106554	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"医美概念股","latestPrice":842.6205,"timestamp":1781770086708,"preClose":840.4199,"halted":0,"volume":74362246,"delay":0,"changeRate":0.002618,"floatShares":0,"shares":0,"eps":0,"marketStatus":"端午节休市","change":2.200562,"latestTime":"06-18 16:00:00","open":840.4926,"high":862.0841,"low":827.59796,"amount":816321291,"amplitude":0.041034,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1781746200000,1781755200000],[1781758800000,1781769600000]],"pbRate":1.106554,"peRate":9.953688,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1593","defaultTab":"news","newsList":[{"id":"2644732297","title":"【券商聚焦】中信建投：建议2026年加配医疗器械板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2644732297","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644732297?lang=zh_cn&edition=full","pubTime":"2026-06-18 09:24","pubTimestamp":1781745845,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券建议，2026年加配医疗器械板块，短期来看，建议把握2026年业绩改善个股的业绩和估值修复机会，多家医疗器械行业细分赛道龙头公司将于2026年迎来加速增长，同时建议关注手术机器人、脑机接口等新科技方向，相关技术突破和商业化落地有望持续催化板块热度。长期来看，医疗器械板块投资机会来自创新、出海和并购整合，板块的创新和国际化能力得到认可，估值正在重构。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984058","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0287142896.SGD","06826","BK1501","BK0276","BK1574","BK1189","02190","00853","BK1222","601066","01302","159883","BK1583","BK1100","BK1600","BK1591","BK1571","BK1247","BK1615","02252","BK1515","BK1585","00241","BK1589","BK1610","HK0000165453.HKD","BK1584","BK1502","BK1161","01066","BK1587","BK1593","09996","02235","LU0173614495.USD","BK1617","BK1142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745441","title":"康哲药业(00867)6月17日斥资411.12万港元回购40万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745441","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644745441?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:09","pubTimestamp":1781698195,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业(00867)发布公告，于2026年6月17日，该公司斥资411.12万港元回购40万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BVYPNP33.GBP","SG9999015986.USD","IE00BVYPNQ40.USD","00867","IE00BMCWC346.EUR","IE00BYV24P56.USD","BK1191","LU2488822045.USD","IE00BGHQDM52.EUR","SG9999015952.SGD","SG9999004220.SGD","BK1593","SG9999015978.USD","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644931743","title":"执行董事唐敏捷增持昊海生科(06826)5000股 每股作价16.12港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644931743","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644931743?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:02","pubTimestamp":1781694143,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，6月16日，执行董事唐敏捷增持昊海生科(06826)5000股，每股作价16.12港元，总金额约为8.06万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260617/20260617190330_44960.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260617/20260617190330_44960.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","EWH","06826","BK1593","688366","BK0251","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644504748","title":"现代牙科(03600)6月17日斥资42.27万港元回购7.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644504748","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644504748?lang=zh_cn&edition=full","pubTime":"2026-06-17 18:52","pubTimestamp":1781693527,"startTime":"0","endTime":"0","summary":"智通财经APP讯，现代牙科(03600)发布公告，该公司于2026年6月17日斥资42.27万港元回购7.3万股股份，每股回购价格为5.79港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","03600","BK1100","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644712432","title":"复星医药（600196）披露2025年度股东会等三会决议公告，6月17日股价下跌1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644712432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644712432?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:26","pubTimestamp":1781688404,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，复星医药报收于21.58元，较前一交易日下跌1.24%，最新总市值为576.28亿元。该股当日开盘21.8元，最高21.95元，最低21.48元，成交额达3.96亿元，换手率为0.86%。近日，复星医药发布《2025年度股东会、2026年第二次A股类别股东会及2026年第二次H股类别股东会决议公告》。公告显示，公司于2026年6月16日召开上述三会，会议由董事会召集，董事长陈玉卿主持。出席会议的股东及代理人共1,467人，代表有表决权股份总数的41.4845%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700030021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0183","BK0060","BK1515","BK0196","BK1191","BK0239","BK0187","600196","02196","BK1593","BK0012","BK0175","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644471213","title":"复星医药最新公告：控股子公司药品HLX3902获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2644471213","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644471213?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:26","pubTimestamp":1781688401,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖收到国家药监局批准，同意HLX3902注射液用于转移性去势抵抗性前列腺癌及其他晚期实体瘤治疗开展Ⅰ期临床试验。该药品为本集团自主研发的三特异性抗体药物，截至公告日全球尚无同类产品获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700029944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","600196","02196","BK0096","BK0012","BK1593","BK0060","BK0028","BK0183","BK0187","BK0188","BK1515","BK0239","BK0196","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644149597","title":"复星医药(600196.SH)控股子公司通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2644149597","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644149597?lang=zh_cn&edition=full","pubTime":"2026-06-17 16:58","pubTimestamp":1781686697,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物医药有限公司收到上海市药品监督管理局颁发的《药品GMP符合性检查告知书》，其位于上海市松江区的生产基地已通过针对帕妥珠单抗注射液(中国境内商品名：汉倍优®)的药品生产质量规范符合性检查(即GMP符合性检查)。检查范围：原液(DS)生产东线、制剂(DP)生产线及包装线。本次通过GMP符合性检查，标志着帕妥珠单抗注射液的相关生产设施已符合《药品生产质量管理规范》的标准，为该药品中国境内的商业化生产与供应奠定基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK0012","BK0187","BK0060","BK0183","BK0188","BK0239","BK1515","600196","BK0175","02196","BK0028","BK0096","BK1191","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644989837","title":"捡漏“弃药”押注联合疗法应世生物深度捆绑“复星系”闯关港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2644989837","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644989837?lang=zh_cn&edition=full","pubTime":"2026-06-17 04:50","pubTimestamp":1781643034,"startTime":"0","endTime":"0","summary":"曾被跨国药企勃林格殷格翰弃用的FAK抑制剂，如今成了应世生物（InxMedLimited）冲刺港股18A的核心筹码。这家企业低价接手海外“弃药”，跳出行业过往“单药治疗”路径，主打联合疗法，将FAK抑制剂作为“基石药物”嵌套进化疗/ADC/免疫治疗的组合方案中，试图实现资产价值重估。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606173773483484.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606173773483484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0196","BK0096","BK0175","BK0188","BK0060","BK1515","BK4007","PROC","02196","BK0028","BK1191","BK0187","BK1593","600196","BK0012","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643676884","title":"复星医药(02196)将于8月14日派发末期股息每股0.39元","url":"https://stock-news.laohu8.com/highlight/detail?id=2643676884","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643676884?lang=zh_cn&edition=full","pubTime":"2026-06-16 21:38","pubTimestamp":1781617127,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，该公司将于2026年8月14日派发截至2025年12月31日止年度的末期股息每股0.39元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK0012","BK0187","BK0060","BK0183","BK0188","BK0239","BK1515","VIG","BK4588","600196","BK0175","02196","BK4585","BK0028","BK0096","BK1191","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643666758","title":"异动股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643666758","media":"财华网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643666758?lang=zh_cn&edition=full","pubTime":"2026-06-16 16:25","pubTimestamp":1781598305,"startTime":"0","endTime":"0","summary":"06月16日收盘，截至发稿，港股涨幅榜前十名分别为浦江中国涨幅+87.170%、东江环保涨幅+39.630%、安宁控股涨幅+35.000%、巨美集团涨幅+34.000%、卓珈控股涨幅+30.880%、时富金融服务集团涨幅+28.770%、冠轈控股涨幅+28.220%、华盛国际控股涨幅+27.980%、大象未来集团涨幅+27.820%、高丰集团控股涨幅+26.000%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/06/16162557488227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1158","01827","BK1552","01323","BK1114","00510","BK1128","00128","01920","BK1230","BK1140","00895","BK1107","BK1542","02863","01872","BK1148","BK1537","01417","BK1147","BK1135","02309","BK1215","BK1239","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643093780","title":"医美概念股普跌 三生制药(01530)下挫5.67% 机构指市场逐步由流量竞争转向品牌竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2643093780","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643093780?lang=zh_cn&edition=full","pubTime":"2026-06-16 10:25","pubTimestamp":1781576726,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念股普跌，截至发稿，三生制药(01530)跌5.67%，四环医药(00460)跌4.30%，巨子生物(02367)跌2.06%，复锐医疗科技(01696)跌1.98%，山东新华制药股份(00719)跌1.91%，昊海生物科技(06826)跌1.90%。消息面上，华龙证券表示，行业层面，医美市场逐步由流量竞争转向品牌竞争，精细化运营及长期用户管理成为机构提升竞争力的重要方向。产品层面，胶原蛋白注射产品商业化落地持续推进，行业发展重心正由传统填充向组织修复、皮肤质量改善及长期抗衰升级。长期来看，具备核心研发能力及品牌运营优势的企业有望持续受益于行业高质量发展趋势。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983863","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01696","06826","LU2488822045.USD","BK1191","BK1583","00460","BK1585","BK1515","BK1600","SG9999004311.SGD","BK1161","01530","02367","00719","BK1100","HK0000165453.HKD","BK1593","BK1207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108470670","title":"复星医药Luvometinib片新增适应症药品注册申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1108470670","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108470670?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:29","pubTimestamp":1781526556,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司宣布，其Luvometinib片新增适应症的药品注册申请已正式获得中国国家药品监督管理局的批准。此次获批标志着该药物在已获准的适应症基础上，其治疗范围将进一步扩大，有望惠及更广泛的患者群体。Luvometinib片是一种创新药物，此次新增适应症的批准，不仅丰富了公司的产品管线，也为其在相关治疗领域的市场拓展提供了新的动力。公司将继续推进该药物的后续研发及商业化进程，以满足临床未尽的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK1593","BK1191","600196","BK0060","BK0096","02196","BK0028","BK0175","BK0187","BK0183","BK1515","BK0239","BK0196","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643205502","title":"执行董事唐敏捷增持昊海生物科技(06826)0.5万股 每股作价16.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2643205502","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643205502?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:07","pubTimestamp":1781525254,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，6月12日，执行董事唐敏捷增持昊海生物科技(06826)0.5万股，每股作价16.2港元，总金额为8.1万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260615/20260615200800_32621.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260615/20260615200800_32621.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","BK1161","06826","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643208779","title":"9.68亿元“补血”：复星医药子公司复星安特金增资扩股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643208779","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643208779?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:41","pubTimestamp":1781523660,"startTime":"0","endTime":"0","summary":"6月15日，复星医药（600196/02196）发布公告，控股子公司复星安特金拟以每股84.207235元的价格向4方投资人新增发行合计1150万股股份，约占本次增资扩股后复星安特金股份总数的12.15%。其中，外部投资人拟出资合计4.18亿元认购共计496万股，公司控股子公司复星医药产业（复星安特金之直接控股股东）拟出资5.5亿元认购653万股。本次增资扩股不构成关联交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606153771725887.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","BK0175","BK0183","02196","BK0188","BK0012","BK0096","BK1191","600196","BK1515","BK0028","BK1593","BK0196","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2643270025","title":"复星医药最新公告：控股子公司药品芦沃美替尼片新增适应症获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2643270025","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643270025?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:19","pubTimestamp":1781522392,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司上海复星医药产业发展有限公司的药品芦沃美替尼片(商品名：复迈宁)新增适应症的药品注册申请获国家药监局批准，本次获批的新适应症为用于2岁及2岁以上经系统治疗后复发或难治的朗格汉斯细胞组织细胞增生症(LCH)儿童及青少年患者。该药品为本集团自主研发的MEK1/2选择性抑制剂，截至公告日，累计研发投入约6.99亿元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500028452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0187","BK0183","BK0196","BK1515","BK1593","BK1191","BK0239","BK0012","600196","BK0096","BK0175","02196","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228694","title":"三生制药获汇添富基金增持63.65万股 每股作价约16.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228694","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643228694?lang=zh_cn&edition=full","pubTime":"2026-06-15 07:17","pubTimestamp":1781479020,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新数据显示，6月10日，汇添富基金管理股份有限公司增持三生制药（01530）63.65万股，每股作价16.2753港元，总金额约为1035.92万港元。增持后最新持股数目约为1.78亿股，持股比例为7%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-06-15/doc-inicmsvf5184093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","EWH","BK1161","01530","HK0000165453.HKD","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643524924","title":"时代天使发布三大核心成果 引领隐形正畸新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2643524924","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643524924?lang=zh_cn&edition=full","pubTime":"2026-06-14 17:24","pubTimestamp":1781429040,"startTime":"0","endTime":"0","summary":"本报讯（记者李春莲）近日，第十二届时代天使A-TECH创新大会在无锡举办，以“溯本源，跃新境”为主题，汇聚正畸领域专家、医生与行业伙伴，共探隐形矫治前沿发展。时代天使科技有限公司（以下简称“时代天使”）在大会上重磅发布新一代A6下颌前导解决方案、A11深覆合解决方案、iOrtho2026智能诊疗管理平台三大创新成果，全面提升诊疗精准度与效率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606143770703672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06699","BK1593","BK1587","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642933772","title":"汇添富基金管理股份有限公司增持三生制药(01530)63.65万股 每股作价约16.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642933772","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642933772?lang=zh_cn&edition=full","pubTime":"2026-06-12 19:58","pubTimestamp":1781265489,"startTime":"0","endTime":"0","summary":"增持后最新持股数目约为1.78亿股，持股比例为7%。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260612/20260612195838_56755.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260612/20260612195838_56755.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","HK0000165453.HKD","EWH","BK1583","01530","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642640070","title":"异动股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642640070","media":"财华网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642640070?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:25","pubTimestamp":1781166308,"startTime":"0","endTime":"0","summary":"06月11日收盘，截至发稿，港股跌幅榜前十名分别为华津国际控股跌幅31.670%、卓珈控股跌幅25.270%、环科国际跌幅23.400%、擎华控股跌幅22.730%、鼎立资本跌幅22.220%、能源及能量环球跌幅21.000%、生活概念跌幅19.480%、国际精密跌幅19.090%、协同通信跌幅18.280%、深演智能跌幅18.230%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/06/11162557428058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1156","BK1124","BK1225","02723","BK1233","01827","00929","01142","00657","01613","BK1529","BK1605","08056","BK1149","BK1128","00356","BK1183","BK1593","BK1215","08082","BK1585","02738"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642410609","title":"三生制药午后涨逾6% 获董事长增持涉资约786.88万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642410609","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642410609?lang=zh_cn&edition=full","pubTime":"2026-06-10 13:51","pubTimestamp":1781070660,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　三生制药（01530）盘中涨超7%，截至发稿，股价上涨5.97%，现报16.33港元，成交额5.78亿港元。\n　　香港联交所最新数据显示，6月8日，董事长兼首席执行官娄竞增持三生制药51.6万股，每股作价15.2497港元，总金额约为786.88万港元。增持后最新持股数目约为5.34亿股，最新持股比例为21.03%。中邮证券此前指出，公司坐拥特比澳等多个现金牛品种，为研发创新输入动力。707授权已落地，增厚公司利润的同时降低了在全球市场拓展的风险敞口。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-06-10/doc-iniawxzs6005122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01530","BK1593","BK1583","HK0000165453.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0726},{"period":"3month","weight":-0.0535},{"period":"6month","weight":-0.0687},{"period":"1year","weight":0.009},{"period":"ytd","weight":-0.0666}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1593","nameEN":"BK1593"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医美概念股,BK1593,医美概念股股票,医美概念股股票老虎,医美概念股股票老虎国际,医美概念股行情,医美概念股股票行情,医美概念股股价,医美概念股股市,医美概念股股票价格,医美概念股股票交易,医美概念股股票购买,医美概念股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}